These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39386278)

  • 61. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
    Saravolatz LD; Depcinski S; Sharma M
    Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Genetic diversity and genomic epidemiology of SARS-CoV-2 during the first 3 years of the pandemic in Morocco: comprehensive sequence analysis, including the unique lineage B.1.528 in Morocco.
    Djorwé S; Malki A; Nzoyikorera N; Nyandwi J; Zebsoubo SP; Bellamine K; Bousfiha A
    Access Microbiol; 2024; 6(10):. PubMed ID: 39376591
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Theoretical insights into the binding interaction of Nirmatrelvir with SARS-CoV-2 Mpro mutants (C145A and C145S): MD simulations and binding free-energy calculation to understand drug resistance.
    Purohit P; Panda M; Muya JT; Bandyopadhyay P; Meher BR
    J Biomol Struct Dyn; 2024 Oct; 42(17):8865-8884. PubMed ID: 37599474
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.
    Iketani S; Mohri H; Culbertson B; Hong SJ; Duan Y; Luck MI; Annavajhala MK; Guo Y; Sheng Z; Uhlemann AC; Goff SP; Sabo Y; Yang H; Chavez A; Ho DD
    bioRxiv; 2022 Aug; ():. PubMed ID: 36032976
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.
    Colaneri M; Scaglione G; Fassio F; Galli L; Lai A; Bergna A; Gabrieli A; Tarkowski M; Ventura CD; Colombo V; Cordier L; Bernasconi D; Corbellino M; Dedivitiis G; Borghetti S; Visigalli D; Sollima S; Casalini G; Rizzardini G; Gori A; Antinori S; Riva A; Schiavini M
    Virol J; 2024 Mar; 21(1):68. PubMed ID: 38509536
    [TBL] [Abstract][Full Text] [Related]  

  • 66. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    Cao Z; Gao W; Bao H; Feng H; Mei S; Chen P; Gao Y; Cui Z; Zhang Q; Meng X; Gui H; Wang W; Jiang Y; Song Z; Shi Y; Sun J; Zhang Y; Xie Q; Xu Y; Ning G; Gao Y; Zhao R
    N Engl J Med; 2023 Feb; 388(5):406-417. PubMed ID: 36577095
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.
    Dryden-Peterson S; Kim A; Kim AY; Caniglia EC; Lennes IT; Patel R; Gainer L; Dutton L; Donahue E; Gandhi RT; Baden LR; Woolley AE
    Ann Intern Med; 2023 Jan; 176(1):77-84. PubMed ID: 36508742
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study.
    Aggarwal NR; Beaty LE; Bennett TD; Fish LE; Jacobs JR; Mayer DA; Molina KC; Peers JL; Richardson DB; Russell S; Varela A; Webb BJ; Wynia MK; Xiao M; Carlson NE; Ginde AA
    Lancet Reg Health Am; 2024 Mar; 31():100693. PubMed ID: 38500962
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12-17 years following SARS-CoV-2 Omicron infection: A target trial emulation.
    Wong CKH; Lau KTK; Au ICH; Chan SHS; Lau EHY; Cowling BJ; Leung GM
    Nat Commun; 2024 Jun; 15(1):4917. PubMed ID: 38851796
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data.
    Petrakis V; Rafailidis P; Trypsianis G; Papazoglou D; Panagopoulos P
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112956
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening.
    Sasi VM; Ullrich S; Ton J; Fry SE; Johansen-Leete J; Payne RJ; Nitsche C; Jackson CJ
    Biochemistry; 2022 Nov; 61(22):2495-2505. PubMed ID: 36326185
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
    Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
    J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
    [TBL] [Abstract][Full Text] [Related]  

  • 73. H172Y mutation perturbs the S1 pocket and nirmatrelvir binding of SARS-CoV-2 main protease through a nonnative hydrogen bond.
    de Oliveira VM; Ibrahim MF; Sun X; Hilgenfeld R; Shen J
    Res Sq; 2022 Aug; ():. PubMed ID: 35982654
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Emerging SARS-CoV-2 Resistance After Antiviral Treatment.
    Tamura TJ; Choudhary MC; Deo R; Yousuf F; Gomez AN; Edelstein GE; Boucau J; Glover OT; Barry M; Gilbert RF; Reynolds Z; Li Y; Tien D; Vyas TD; Passell E; Su K; Drapkin S; Abar EG; Kawano Y; Sparks JA; Wallace ZS; Vyas JM; Shafer RW; Siedner MJ; Barczak AK; Lemieux JE; Li JZ;
    JAMA Netw Open; 2024 Sep; 7(9):e2435431. PubMed ID: 39320890
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Baseline Sequencing Surveillance of Public Clinical Testing, Hospitals, and Community Wastewater Reveals Rapid Emergence of SARS-CoV-2 Omicron Variant of Concern in Arizona, USA.
    Smith MF; Holland SC; Lee MB; Hu JC; Pham NC; Sullins RA; Holland LA; Mu T; Thomas AW; Fitch R; Driver EM; Halden RU; Villegas-Gold M; Sanders S; Krauss JL; Nordstrom L; Mulrow M; White M; Murugan V; Lim ES
    mBio; 2023 Feb; 14(1):e0310122. PubMed ID: 36622143
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease.
    Noske GD; de Souza Silva E; de Godoy MO; Dolci I; Fernandes RS; Guido RVC; Sjö P; Oliva G; Godoy AS
    J Biol Chem; 2023 Mar; 299(3):103004. PubMed ID: 36775130
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models.
    Cox RM; Lieber CM; Wolf JD; Karimi A; Lieberman NAP; Sticher ZM; Roychoudhury P; Andrews MK; Krueger RE; Natchus MG; Painter GR; Kolykhalov AA; Greninger AL; Plemper RK
    Nat Commun; 2023 Aug; 14(1):4731. PubMed ID: 37550333
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Synergistic Activity of Remdesivir-Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report.
    Gidari A; Sabbatini S; Schiaroli E; Bastianelli S; Pierucci S; Busti C; Saraca LM; Capogrossi L; Pasticci MB; Francisci D
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515263
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Recent changes in the mutational dynamics of the SARS-CoV-2 main protease substantiate the danger of emerging resistance to antiviral drugs.
    Parigger L; Krassnigg A; Schopper T; Singh A; Tappler K; Köchl K; Hetmann M; Gruber K; Steinkellner G; Gruber CC
    Front Med (Lausanne); 2022; 9():1061142. PubMed ID: 36590977
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Resistance-associated mutations to the anti-SARS-CoV-2 agent nirmatrelvir: Selection not induction.
    Colson P; Delerce J; Pontarotti P; Devaux C; La Scola B; Fantini J; Raoult D
    J Med Virol; 2024 Feb; 96(2):e29462. PubMed ID: 38363015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.